Literature DB >> 29128670

Synchronous immune alterations mirror clinical response during allergen immunotherapy.

Amedee Renand1, Mohamed H Shamji2, Kristina M Harris3, Tielin Qin3, Erik Wambre1, Guy W Scadding4, Peter A Wurtzen5, Stephen J Till6, Alkis Togias7, Gerald T Nepom8, William W Kwok1, Stephen R Durham9.   

Abstract

BACKGROUND: Three years of treatment with either sublingual or subcutaneous allergen immunotherapy has been shown to be effective and to induce long-term tolerance. The Gauging Response in Allergic Rhinitis to Sublingual and Subcutaneous Immunotherapy (GRASS) trial demonstrated that 2 years of treatment through either route was effective in suppressing the response to nasal allergen challenge, although it was insufficient for inhibition 1 year after discontinuation.
OBJECTIVE: We sought to examine in the GRASS trial the time course of immunologic changes during 2 years of sublingual and subcutaneous immunotherapy and for 1 year after treatment discontinuation.
METHODS: We performed multimodal immunomonitoring to assess allergen-specific CD4 T-cell properties in parallel with analysis of local mucosal cytokine responses induced by nasal allergen exposure and humoral immune responses that included IgE-dependent basophil activation and measurement of serum inhibitory activity for allergen-IgE binding to B cells (IgE-facilitated allergen binding).
RESULTS: All 3 of these distinct arms of the immune response displayed significant and coordinate alterations during 2 years of allergen desensitization, followed by reversal at 3 years, reflecting a lack of a durable immunologic effect. Although frequencies of antigen-specific TH2 cells in peripheral blood determined by using HLA class II tetramer analysis most closely paralleled clinical outcomes, IgE antibody-dependent functional assays remained inhibited in part 1 year after discontinuation.
CONCLUSION: Two years of allergen immunotherapy were effective but insufficient for long-term tolerance. Allergen-specific TH2 cells most closely paralleled the transient clinical outcome, and it is likely that recurrence of the T-cell drivers of allergic immunity abrogated the potential for durable tolerance. On the other hand, the persistence of IgE blocking antibody 1 year after discontinuation might be an early indicator of a protolerogenic mechanism.
Copyright © 2017 American Academy of Allergy, Asthma & Immunology. All rights reserved.

Entities:  

Keywords:  Allergy; T(H)2 cells; allergen desensitization; immune tolerance; immunotherapy

Mesh:

Substances:

Year:  2017        PMID: 29128670      PMCID: PMC5938141          DOI: 10.1016/j.jaci.2017.09.041

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  50 in total

1.  Grass pollen immunotherapy inhibits seasonal increases in basophils and eosinophils in the nasal epithelium.

Authors:  D R Wilson; A M Irani; S M Walker; M R Jacobson; I S Mackay; L B Schwartz; S R Durham
Journal:  Clin Exp Allergy       Date:  2001-11       Impact factor: 5.018

2.  Direct access to CD4+ T cells specific for defined antigens according to CD154 expression.

Authors:  Marco Frentsch; Olga Arbach; Dennis Kirchhoff; Beate Moewes; Margitta Worm; Martin Rothe; Alexander Scheffold; Andreas Thiel
Journal:  Nat Med       Date:  2005-09-25       Impact factor: 53.440

3.  IL-9 and c-Kit+ mast cells in allergic rhinitis during seasonal allergen exposure: effect of immunotherapy.

Authors:  Kayhan T Nouri-Aria; Charles Pilette; Mikila R Jacobson; Hiroshi Watanabe; Stephen R Durham
Journal:  J Allergy Clin Immunol       Date:  2005-07       Impact factor: 10.793

4.  Effect of 2 Years of Treatment With Sublingual Grass Pollen Immunotherapy on Nasal Response to Allergen Challenge at 3 Years Among Patients With Moderate to Severe Seasonal Allergic Rhinitis: The GRASS Randomized Clinical Trial.

Authors:  Guy W Scadding; Moises A Calderon; Mohamed H Shamji; Aarif O Eifan; Martin Penagos; Florentina Dumitru; Michelle L Sever; Henry T Bahnson; Kaitie Lawson; Kristina M Harris; Audrey G Plough; Joy Laurienzo Panza; Tielin Qin; Noha Lim; Nadia K Tchao; Alkis Togias; Stephen R Durham
Journal:  JAMA       Date:  2017-02-14       Impact factor: 56.272

5.  Grass pollen immunotherapy: IL-10 induction and suppression of late responses precedes IgG4 inhibitory antibody activity.

Authors:  James N Francis; Louisa K James; Giannis Paraskevopoulos; Cheukyee Wong; Moises A Calderon; Stephen R Durham; Stephen J Till
Journal:  J Allergy Clin Immunol       Date:  2008-04-18       Impact factor: 10.793

6.  Long-term tolerance after allergen immunotherapy is accompanied by selective persistence of blocking antibodies.

Authors:  Louisa K James; Mohamed H Shamji; Samantha M Walker; Duncan R Wilson; Petra A Wachholz; James N Francis; Mikila R Jacobson; Ian Kimber; Stephen J Till; Stephen R Durham
Journal:  J Allergy Clin Immunol       Date:  2011-02       Impact factor: 10.793

7.  Distinct modulation of allergic T cell responses by subcutaneous vs. sublingual allergen-specific immunotherapy.

Authors:  V Schulten; V Tripple; K Aasbjerg; V Backer; G Lund; P A Würtzen; A Sette; B Peters
Journal:  Clin Exp Allergy       Date:  2016-03       Impact factor: 5.018

8.  Early oral immunotherapy in peanut-allergic preschool children is safe and highly effective.

Authors:  Brian P Vickery; Jelena P Berglund; Caitlin M Burk; Jason P Fine; Edwin H Kim; Jung In Kim; Corinne A Keet; Michael Kulis; Kelly G Orgel; Rishu Guo; Pamela H Steele; Yamini V Virkud; Ping Ye; Benjamin L Wright; Robert A Wood; A Wesley Burks
Journal:  J Allergy Clin Immunol       Date:  2016-08-10       Impact factor: 10.793

9.  Biomarkers for monitoring clinical efficacy of allergen immunotherapy for allergic rhinoconjunctivitis and allergic asthma: an EAACI Position Paper.

Authors:  M H Shamji; J H Kappen; M Akdis; E Jensen-Jarolim; E F Knol; J Kleine-Tebbe; B Bohle; A M Chaker; S J Till; R Valenta; L K Poulsen; M A Calderon; P Demoly; O Pfaar; L Jacobsen; S R Durham; C B Schmidt-Weber
Journal:  Allergy       Date:  2017-04-06       Impact factor: 13.146

10.  Specific immunotherapy modifies allergen-specific CD4(+) T-cell responses in an epitope-dependent manner.

Authors:  Erik Wambre; Jonathan H DeLong; Eddie A James; Nadia Torres-Chinn; Wolfgang Pfützner; Christian Möbs; Stephen R Durham; Stephen J Till; David Robinson; William W Kwok
Journal:  J Allergy Clin Immunol       Date:  2013-12-25       Impact factor: 10.793

View more
  14 in total

1.  Sublingual immunotherapy for food allergy and its future directions.

Authors:  Stephen A Schworer; Edwin H Kim
Journal:  Immunotherapy       Date:  2020-07-02       Impact factor: 4.196

2.  Oral desensitization therapy for peanut allergy induces dynamic changes in peanut-specific immune responses.

Authors:  Veronique Bajzik; Hannah A DeBerg; Nahir Garabatos; Blake J Rust; Kimberly K Obrien; Quynh-Anh Nguyen; Colin O'Rourke; Alex Smith; Alex H Walker; Charlie Quinn; Vivian H Gersuk; Mary Farrington; David Jeong; Brian P Vickery; Daniel C Adelman; Erik Wambre
Journal:  Allergy       Date:  2022-03-14       Impact factor: 14.710

3.  Unsupervised capture and profiling of rare immune cells using multi-directional magnetic ratcheting.

Authors:  Coleman Murray; Hiromi Miwa; Manjima Dhar; Da Eun Park; Edward Pao; Jessica Martinez; Sireesha Kaanumale; Evelina Loghin; John Graf; Khadir Raddassi; William W Kwok; David Hafler; Chris Puleo; Dino Di Carlo
Journal:  Lab Chip       Date:  2018-08-07       Impact factor: 6.799

Review 4.  Is Allergen Immunotherapy in Children Disease Modifying? A Review of the Evidence.

Authors:  Amanda K Rudman Spergel; Michael Minnicozzi; Lisa M Wheatley; Alkis Togias
Journal:  Curr Allergy Asthma Rep       Date:  2018-07-11       Impact factor: 4.806

5.  Nasal allergen challenge and environmental exposure chamber challenge: A randomized trial comparing clinical and biological responses to cat allergen.

Authors:  David Larson; Piyush Patel; Anne Marie Salapatek; Peter Couroux; Don Whitehouse; Adela Pina; Jacqueline L Johnson; Michelle L Sever; Srinath Sanda; Julian Poyser; Theresa Allio; Guy W Scadding; Tielin Qin; Mohamed H Shamji; William W Kwok; Eddie A James; Deanna French; Alina Lelic; Mark Larché; Matthew C Altman; Alkis Togias; Stephen R Durham
Journal:  J Allergy Clin Immunol       Date:  2020-03-10       Impact factor: 10.793

6.  A preseason booster prolongs the increase of allergen specific IgG4 levels, after basic allergen intralymphatic immunotherapy, against grass pollen seasonal allergy.

Authors:  Dan Weinfeld; Ulla Westin; Laila Hellkvist; Ulf-Henrik Mellqvist; Ingvar Jacobsson; Lars-Olaf Cardell
Journal:  Allergy Asthma Clin Immunol       Date:  2020-04-28       Impact factor: 3.406

7.  A Sensitive Whole Blood Assay Detects Antigen-Stimulated Cytokine Release From CD4+ T Cells and Facilitates Immunomonitoring in a Phase 2 Clinical Trial of Nexvax2 in Coeliac Disease.

Authors:  Melinda Y Hardy; Gautam Goel; Amy K Russell; Swee Lin G Chen Yi Mei; Gregor J E Brown; Suyue Wang; Evan Szymczak; Ruan Zhang; Kaela E Goldstein; Kristin M Neff; Leslie J Williams; Kenneth E Truitt; John L Dzuris; Jason A Tye-Din; Robert P Anderson
Journal:  Front Immunol       Date:  2021-05-19       Impact factor: 7.561

Review 8.  Duration of Allergen Immunotherapy for Long-Term Efficacy in Allergic Rhinoconjunctivitis.

Authors:  Martin Penagos; Aarif O Eifan; Stephen R Durham; Guy W Scadding
Journal:  Curr Treat Options Allergy       Date:  2018-08-31

9.  Modulating Shrimp Tropomyosin-Mediated Allergy: Hypoallergen DNA Vaccines Induce Regulatory T Cells to Reduce Hypersensitivity in Mouse Model.

Authors:  Christine Y Y Wai; Nicki Y H Leung; Patrick S C Leung; Ka Hou Chu
Journal:  Int J Mol Sci       Date:  2019-09-19       Impact factor: 5.923

Review 10.  Allergen-Specific Antibodies Regulate Secondary Allergen-Specific Immune Responses.

Authors:  Julia Eckl-Dorna; Sergio Villazala-Merino; Birgit Linhart; Alexander V Karaulov; Yury Zhernov; Musa Khaitov; Verena Niederberger-Leppin; Rudolf Valenta
Journal:  Front Immunol       Date:  2019-01-17       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.